TY - JOUR
T1 - Mantle cell lymphoma
T2 - Frontline and salvage therapy
AU - Romaguera, Jorge E.
PY - 2008
Y1 - 2008
N2 - Mantle cell lymphoma (MCL) is a therapeutic challenge because of its lower cure rate when compared with other lymphomas such as diffuse large cell lymphoma. The current emphasis in the treatment of newly diagnosed MCL has been on intensifying chemotherapy, but there is no consensus on the need to consolidate with autologous stem cell transplantation. These approaches, however, have not resulted in a cure. Newer strategies include the use of models to aid in tailoring therapy. Likewise, autologous stem cell consolidation does not cure relapsed disease. Because of its known graft-versus-lymphoma effect, allogeneic stem cell transplantation offers a potentially curative option for relapsed MCL. New insights into resistance pathways and new drugs created to inhibit them offer great promise in the treatment of newly diagnosed and previously treated MCL.
AB - Mantle cell lymphoma (MCL) is a therapeutic challenge because of its lower cure rate when compared with other lymphomas such as diffuse large cell lymphoma. The current emphasis in the treatment of newly diagnosed MCL has been on intensifying chemotherapy, but there is no consensus on the need to consolidate with autologous stem cell transplantation. These approaches, however, have not resulted in a cure. Newer strategies include the use of models to aid in tailoring therapy. Likewise, autologous stem cell consolidation does not cure relapsed disease. Because of its known graft-versus-lymphoma effect, allogeneic stem cell transplantation offers a potentially curative option for relapsed MCL. New insights into resistance pathways and new drugs created to inhibit them offer great promise in the treatment of newly diagnosed and previously treated MCL.
UR - http://www.scopus.com/inward/record.url?scp=59349098919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59349098919&partnerID=8YFLogxK
U2 - 10.1007/s11899-008-0029-3
DO - 10.1007/s11899-008-0029-3
M3 - Review article
C2 - 20425467
AN - SCOPUS:59349098919
SN - 1558-8211
VL - 3
SP - 204
EP - 209
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 4
ER -